OpenAI acquires a16z-backed Orchestra Bio to build life sciences agents
a16z · x · 2026-10-21
a16z confirms that its portfolio company Orchestra Bio has been acquired by OpenAI. The Orchestra team will join OpenAI to develop agent applications for life sciences, marking OpenAI's expansion into AI-driven biotech talent and capabilities.
Related event: OpenAI Acquires Orchestra Bio to Double Down on AI-Driven Drug Development(11 posts)→
More from Companies & People
- OpenAI goes quiet on China chip export controls as Congress weighs new limits — rohanpaul_ai · 2026-10-21
- a16z's Casado says AI can't do a VC's job — but it can do everything around it — alvelda · 2026-10-21
- Ex-Meta Integrity engineer praises Zuck's shift from fact-checkers to Community Notes — HarperSCarroll · 2026-10-21
- Nyne, under 15 people with tens of millions in monthly revenue, hires SPLs and RL engineers — soleio · 2026-10-21
- UNESCO and ICOM Release 2026 Report on AI Use in Museums Across 90 Countries — LuizaJarovsky · 2026-10-21
- AI app-layer acquisitions are now mostly about founders and customers, not tech — signulll · 2026-10-21